New drug combo shows promise against tough head and neck cancer
NCT ID NCT03650764
First seen Jan 09, 2026 · Last updated May 15, 2026 · Updated 16 times
Summary
This study tested a combination of two drugs, ramucirumab and pembrolizumab, in 43 people with head and neck cancer that had spread or come back. The goal was to see if the combination was safe and effective at shrinking tumors. The trial had two parts: first finding a safe dose, then measuring how well the drugs worked together.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.